ClinicalTrials.gg
CompletedNCT02275351Updated Oct 21, 2026Results posted

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Phase 2 interventional study of Topical SM04554 solution and Topical SM04554 solution in Androgenetic Alopecia, sponsored by Biosplice Therapeutics, Inc.. Completed at 24 sites in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Biosplice Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Results postedPosted results revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
19th of 204
302 · median 40
Started
2014
with 5 others
Phase 2
48 of 217
7 open now
Registered
48th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 19th largest by enrollment of the 204 interventional ones that give a count, is one of 6 that started in 2014, is one of 48 in phase 2, and was the 48th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • alopecia
  • topical
  • Samumed
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of AGA
  • Willing to inform females, with whom they may interact, that they are using a topical product and direct contact should be avoided as potential harm to a fetus is unknown
  • Willing to maintain the same hair style as at study start for the duration of the study
  • Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study. Daily styling products will be allowed (e.g., hair gel, mousse, styling spray).
  • Willing to use a mild non-medicated shampoo and conditioner for the duration of the study
  • Willing to receive a small scalp tattoo
  • Able to read and understand English

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
  • Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  • Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using an effective method of and are not willing to use an effective method of birth control during the study treatment period until 90 days post last dose of study medication
  • Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and/or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
  • History of surgical correction of hair loss on the scalp
  • Previous exposure to SM04554
  • Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 24 weeks prior to study start
  • Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
  • History of hair transplants
  • Current use of an occlusive wig, hair extensions, or hair weaves
  • Participation in any other drug or medical device trial, which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
  • Subjects with a history of cardiac arrhythmia as determined by the Investigator
  • Subjects with clinically significant findings from medical history, clinical laboratory tests, (ECG), or vital signs that, in the opinion of the Investigator, could interfere with the objectives of the study or put the subject at risk
  • Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
  • Subjects with pregnant partners at study start
  • Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
  • Use of medicated shampoo or conditioner within 30 days prior to study start
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Topical SM04554 0.15% solution

    Topical SM04554 0.15% solution, applied once a day for 90 days

    Drug: Topical SM04554 solution

  • Experimental
    Topical SM04554 0.25% solution

    Topical SM04554 0.25% solution, applied once a day for 90 days

    Drug: Topical SM04554 solution

  • Placebo comparator
    Vehicle

    Topical vehicle solution, applied once a day for 90 days

    Drug: Topical vehicle solution

Interventions

  • DrugDalosirvatStudies of DalosirvatDalosirvat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Study medication application will be performed by the individual subject at approximately the same time each day.

  • DrugDalosirvatStudies of DalosirvatDalosirvat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Study medication application will be performed by the individual subject at approximately the same time each day.

  • DrugTopical vehicle solution

    Vehicle solution application will be performed by the individual subject at approximately the same time each day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Non-vellus Hair Count

    Change from baseline in non-vellus hair count over time. Non-vellus hair count was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place.

    Time frame: Day 45, Day 90, and Day 135

  2. Change in Subject Assessment of Hair Growth and Quality

    Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.

    Time frame: Day 45, Day 90, and Day 135

Secondary outcomes

  1. Change in Hair Growth as Assessed by the Investigator

    Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased). Responses were analyzed using logistic regression modeling improvement vs no change/worsening of hair status at each visit.

    Time frame: Day 45, Day 90, and Day 135

  2. Impact of AGA on Quality of Life

    Change from baseline in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time. The KAP is a validated, patient-reported outcome that quantitatively measure the impact androgenetic alopecia on the subject's quality of life. Each of the 38 KAP 5-category Likert-scaled questions was scored +2 'Strongly Agree' to -2 'Strongly Disagree.' The KAP score was summed across all 38 questions for a score ranging from +76 to -76, with higher scores indicating an increasing negative impact on quality of life. Change from baseline was calculated as visit - baseline such that negative values reflecting improving quality of life.

    Time frame: Day 45, Day 90, and Day 135

  3. Change From Baseline in Total Sum of Hair Width

    Non-vellus hair width was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. While the protocol and SAP listed this outcome as hair density, the actual outcome analyzed was the total sum of non-vellus hair width in microns within the target area provided by macrophotography.

    Time frame: Day 45, Day 90, and Day 135

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneSM04554 0.15%SM04554 0.25%Vehicle
Started10210298
Completed747776
Not completed282522
Withdrew: Adverse event111312
Withdrew: Lost to follow-up441
Withdrew: Protocol violation1033
Withdrew: Withdrawal by subject256
Withdrew: Medication dispensing error100

Outcome measures

PrimaryChange From Baseline in Non-vellus Hair Count

Change from baseline in non-vellus hair count over time. Non-vellus hair count was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place.

Time frame:
Day 45, Day 90, and Day 135
Reported as:
Mean · Non-vellus hair count
Change From Baseline in Non-vellus Hair Count
Non-vellus hair countSM04554 0.15%SM04554 0.25%Vehicle
Day 454.6 ± 16.972.6 ± 14.355.7 ± 13.27
Day 90 (Primary efficacy, treatment completion, time point)4.2 ± 17.883.2 ± 15.666.2 ± 14.75
Day 1357.9 ± 17.953.3 ± 15.784.2 ± 18.77
Statistical analysis
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.6869 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -0.9Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.1658 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -3.1Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.4297 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -2.1Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.1569 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -3.6Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.2158 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: 3.6Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.5676 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -1.6Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
PrimaryChange in Subject Assessment of Hair Growth and Quality

Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.

Time frame:
Day 45, Day 90, and Day 135
Reported as:
Count of participants · Participants
Change in Subject Assessment of Hair Growth and Quality
ParticipantsSM04554 0.15%SM04554 0.25%Vehicle
1. Bald spot getting smaller - Day 45 — Worsening553938
1. Bald spot getting smaller - Day 45 — No Change243732
1. Bald spot getting smaller - Day 45 — Improvement132120
1. Bald spot getting smaller - Day 90 — Worsening514440
1. Bald spot getting smaller - Day 90 — No Change142023
1. Bald spot getting smaller - Day 90 — Improvement131817
1. Bald spot getting smaller - Day 135 — Worsening514744
1. Bald spot getting smaller - Day 135 — No Change111819
1. Bald spot getting smaller - Day 135 — Improvement141512
2. Appearance of hair - Day 45 — Worsening10108
2. Appearance of hair - Day 45 — No Change555552
2. Appearance of hair - Day 45 — Improvement273230
2. Appearance of hair - Day 90 — Worsening9135
2. Appearance of hair - Day 90 — No Change524451
2. Appearance of hair - Day 90 — Improvement172524
2. Appearance of hair - Day 135 — Worsening181113
2. Appearance of hair - Day 135 — No Change414543
2. Appearance of hair - Day 135 — Improvement172419
3. Growth of hair - Day 45 — Worsening8105
3. Growth of hair - Day 45 — No Change565048
3. Growth of hair - Day 45 — Improvement283737
3. Growth of hair - Day 90 — Worsening10106
3. Growth of hair - Day 90 — No Change474243
3. Growth of hair - Day 90 — Improvement213031
3. Growth of hair - Day 135 — Worsening131011
3. Growth of hair - Day 135 — No Change444135
3. Growth of hair - Day 135 — Improvement192929
4. Slowing hair loss - Day 45 — Worsening636052
4. Slowing hair loss - Day 45 — No Change000
4. Slowing hair loss - Day 45 — Improvement293738
4. Slowing hair loss - Day 90 — Worsening514843
4. Slowing hair loss - Day 90 — No Change000
4. Slowing hair loss - Day 90 — Improvement273437
4. Slowing hair loss - Day 135 — Worsening605151
4. Slowing hair loss - Day 135 — No Change000
4. Slowing hair loss - Day 135 — Improvement162924
5a. Satisfaction with frontal hairline - Day 45 — Worsening282221
5a. Satisfaction with frontal hairline - Day 45 — No Change516145
5a. Satisfaction with frontal hairline - Day 45 — Improvement131424
5a. Satisfaction with frontal hairline - Day 90 — Worsening312629
5a. Satisfaction with frontal hairline - Day 90 — No Change393635
5a. Satisfaction with frontal hairline - Day 90 — Improvement81915
5a. Satisfaction with frontal hairline - Day 135 — Worsening352622
5a. Satisfaction with frontal hairline - Day 135 — No Change284137
5a. Satisfaction with frontal hairline - Day 135 — Improvement131316
5b. Satisfaction with hair on top - Day 45 — Worsening372731
5b. Satisfaction with hair on top - Day 45 — No Change415042
5b. Satisfaction with hair on top - Day 45 — Improvement142016
5b. Satisfaction with hair on top - Day 90 — Worsening363933
5b. Satisfaction with hair on top - Day 90 — No Change343037
5b. Satisfaction with hair on top - Day 90 — Improvement8128
5b. Satisfaction with hair on top - Day 135 — Worsening374136
5b. Satisfaction with hair on top - Day 135 — No Change282827
5b. Satisfaction with hair on top - Day 135 — Improvement111111
5c. Satisfaction with hair overall - Day 45 — Worsening322630
5c. Satisfaction with hair overall - Day 45 — No Change465340
5c. Satisfaction with hair overall - Day 45 — Improvement141819
5c. Satisfaction with hair overall - Day 90 — Worsening323429
5c. Satisfaction with hair overall - Day 90 — No Change343136
5c. Satisfaction with hair overall - Day 90 — Improvement121512
5c. Satisfaction with hair overall - Day 135 — Worsening322929
5c. Satisfaction with hair overall - Day 135 — No Change313736
5c. Satisfaction with hair overall - Day 135 — Improvement13149
Statistical analysis
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.1248 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.54 · 95% CI 0.248 to 1.185Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.3155 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.66 · 95% CI 0.290 to 1.490Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.6002 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.26 · 95% CI 0.533 to 2.966Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.8161 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.92 · 95% CI 0.456 to 1.858Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.9842 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.01 · 95% CI 0.472 to 2.152Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5931 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.26 · 95% CI 0.542 to 2.917Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.5529 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.82 · 95% CI 0.437 to 1.557Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.1889 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.61 · 95% CI 0.295 to 1.272Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.5780 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.81 · 95% CI 0.377 to 1.723Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.9669 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.99 · 95% CI 0.534 to 1.824Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.9873 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.01 · 95% CI 0.512 to 1.975Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5794 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.22 · 95% CI 0.600 to 2.493Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.0749 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.57 · 95% CI 0.303 to 1.059Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.0736 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.53 · 95% CI 0.269 to 1.062Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.0608 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.51 · 95% CI 0.251 to 1.031Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5383 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.83 · 95% CI 0.457 to 1.506Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.7443 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.90 · 95% CI 0.472 to 1.709Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.7666 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.91 · 95% CI 0.469 to 1.746Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.1830 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.66 · 95% CI 0.356 to 1.218Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.0678 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.54 · 95% CI 0.278 to 1.046Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.1151 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.55 · 95% CI 0.262 to 1.157Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.6499 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.87 · 95% CI 0.483 to 1.574Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.4852 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.80 · 95% CI 0.422 to 1.506Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5993 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.20 · 95% CI 0.612 to 2.341Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.0725 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.50 · 95% CI 0.230 to 1.066Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.1812 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.53 · 95% CI 0.208 to 1.345Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.6068 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.80 · 95% CI 0.352 to 1.839Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.0387 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.45 · 95% CI 0.211 to 0.959Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.4190 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.37 · 95% CI 0.636 to 2.970Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.4166 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.71 · 95% CI 0.313 to 1.617Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.7776 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.89 · 95% CI 0.401 to 1.982Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.9839 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.99 · 95% CI 0.347 to 2.819Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.9795 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.99 · 95% CI 0.395 to 2.473Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.6565 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.18 · 95% CI 0.562 to 2.494Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.3703 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.55 · 95% CI 0.593 to 4.068Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.8526 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.92 · 95% CI 0.368 to 2.284Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.3226 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.68 · 95% CI 0.312 to 1.467Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.9127 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.05 · 95% CI 0.436 to 2.532Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.2845 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.66 · 95% CI 0.655 to 4.223Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5711 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.81 · 95% CI 0.389 to 1.683Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5536 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.29 · 95% CI 0.557 to 2.978Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.3191 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.59 · 95% CI 0.638 to 3.967Logistic Regression Model for Improvement vs No Change/Worsening.
SecondaryChange in Hair Growth as Assessed by the Investigator

Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased). Responses were analyzed using logistic regression modeling improvement vs no change/worsening of hair status at each visit.

Time frame:
Day 45, Day 90, and Day 135
Reported as:
Count of participants · Participants
Change in Hair Growth as Assessed by the Investigator
ParticipantsSM04554 0.15%SM04554 0.25%Vehicle
Day 45 — Worsening346
Day 45 — No Change586158
Day 45 — Improvement303126
Day 90 — Worsening653
Day 90 — No Change465249
Day 90 — Improvement262528
Day 135 — Worsening10712
Day 135 — No Change434939
Day 135 — Improvement232425
Statistical analysis
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.7529 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.11 · 95% CI 0.578 to 2.132Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.9102 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.96 · 95% CI 0.493 to 1.879Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.15% vs Vehicle · Regression, Logistic · p = 0.5367 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.80 · 95% CI 0.399 to 1.613Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.7355 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 1.12 · 95% CI 0.587 to 2.125Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5212 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.80 · 95% CI 0.414 to 1.563Logistic Regression Model for Improvement vs No Change/Worsening.
  • SM04554 0.25% vs Vehicle · Regression, Logistic · p = 0.5897 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Odds ratio (or): 0.83 · 95% CI 0.417 to 1.644Logistic Regression Model for Improvement vs No Change/Worsening.
SecondaryImpact of AGA on Quality of Life

Change from baseline in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time. The KAP is a validated, patient-reported outcome that quantitatively measure the impact androgenetic alopecia on the subject's quality of life. Each of the 38 KAP 5-category Likert-scaled questions was scored +2 'Strongly Agree' to -2 'Strongly Disagree.' The KAP score was summed across all 38 questions for a score ranging from +76 to -76, with higher scores indicating an increasing negative impact on quality of life. Change from baseline was calculated as visit - baseline such that negative values reflecting improving quality of life.

Time frame:
Day 45, Day 90, and Day 135
Reported as:
Mean · score on a scale
Impact of AGA on Quality of Life
score on a scaleSM04554 0.15%SM04554 0.25%Vehicle
Day 45-2.0 ± 12.390.7 ± 15.15-0.6 ± 11.01
Day 90-3.2 ± 14.89-2.1 ± 14.18-1.3 ± 11.97
Day 135-3.7 ± 12.39-0.9 ± 16.32-1.1 ± 13.64
Statistical analysis
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.2937 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -2.0Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.2648 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -2.5Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.1504 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -3.3Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.8011 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: 0.5Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.4888 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -1.5Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.7661 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Least squares estimate of difference: -0.7Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
SecondaryChange From Baseline in Total Sum of Hair Width

Non-vellus hair width was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. While the protocol and SAP listed this outcome as hair density, the actual outcome analyzed was the total sum of non-vellus hair width in microns within the target area provided by macrophotography.

Time frame:
Day 45, Day 90, and Day 135
Reported as:
Mean · microns
Change From Baseline in Total Sum of Hair Width
micronsSM04554 0.15%SM04554 0.25%Vehicle
Day 45105.7 ± 847.77110.6 ± 738.23227.0 ± 754.95
Day 9098.3 ± 966.5941.3 ± 788.52245.7 ± 832.60
Day 135235.4 ± 904.8931.2 ± 814.9343.3 ± 970.88
Statistical analysis
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.3652 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): -108.8Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.2804 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): -152.5Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.15% vs Vehicle · ANCOVA · p = 0.2102 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): 188.6Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.3402 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): -111.4Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.0774 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): -242.3Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.
  • SM04554 0.25% vs Vehicle · ANCOVA · p = 0.7285 (Unadjusted, Bonferroni correction alpha is 0.025 for the two treatment comparisons.) · Mean difference (final values): -51.1Least squares estimate of difference (SM04554 - Vehicle) is based on an adjusted (see Method/Comments section) change from baseline ANCOVA model.

Adverse events

Collected over AEs were assessed at each study visit from the start of study medication application on Day 1 through Day 135 (End of Study) which was 45 days after last application of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SM04554 0.15%0/102 (0%)0/102 (0%)45/102 (44.1%)
SM04554 0.25%0/102 (0%)0/102 (0%)46/102 (45.1%)
Vehicle0/98 (0%)1/98 (1%)47/98 (48%)
Most frequent serious events
Most frequent serious events
EventSM04554 0.15%SM04554 0.25%Vehicle
Small intestinal obstructionGastrointestinal disorders0/1020/1021/98
Most frequent other events
Showing 10 of 96
Most frequent other events
EventSM04554 0.15%SM04554 0.25%Vehicle
Application site erythemaGeneral disorders and administration site conditions5/1027/1025/98
Application site pruritusGeneral disorders and administration site conditions6/1024/1026/98
Application site paraesthesiaGeneral disorders and administration site conditions6/1023/1026/98
Skin exfoliationSkin and subcutaneous tissue disorders2/1023/1026/98
PruritusSkin and subcutaneous tissue disorders1/1024/1021/98
CoughRespiratory, thoracic and mediastinal disorders4/1020/1021/98
HeadacheNervous system disorders1/1021/1023/98
SinusitisInfections and infestations0/1021/1023/98
ErythemaSkin and subcutaneous tissue disorders0/1020/1023/98
NauseaGastrointestinal disorders1/1023/1022/98

Baseline characteristics

All subjects who received at least one dose of study treatment

Age, Continuous
Age, Continuous(years)SM04554 0.15%SM04554 0.25%VehicleTotal
Mean44.2 ± 8.2144.7 ± 8.8345.0 ± 8.6044.6 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)SM04554 0.15%SM04554 0.25%VehicleTotal
Female0000
Male10210298302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SM04554 0.15%SM04554 0.25%VehicleTotal
Hispanic or Latino14221854
Not Hispanic or Latino888080248
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SM04554 0.15%SM04554 0.25%VehicleTotal
American Indian or Alaska Native0011
Asian1102
Native Hawaiian or Other Pacific Islander1203
Black or African American1010626
White898890267
More than one race1113
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)SM04554 0.15%SM04554 0.25%VehicleTotal
United States10210298302
Weight [kg]
Weight [kg](kg)SM04554 0.15%SM04554 0.25%VehicleTotal
Mean95.90 ± 17.33494.15 ± 18.32092.50 ± 19.53594.21 ± 18.394
Height [cm]
Height [cm](cm)SM04554 0.15%SM04554 0.25%VehicleTotal
Mean178.64 ± 7.802177.58 ± 7.731177.46 ± 7.246177.90 ± 7.595
Norwood-Hamilton Classification Score
Norwood-Hamilton Classification Score(Participants)SM04554 0.15%SM04554 0.25%VehicleTotal
4293635100
59141740
5A18112251
5V26221462
620191049
08

Study locations

24 sites
  • Encinitas, California 92024, United States
  • San Diego, California 92123, United States
  • New Haven, Connecticut 06511, United States
  • Miami, Florida 33143, United States
  • West Palm Beach, Florida 33401, United States
  • Plainfield, Indiana, United States
  • Wichita, Kansas 67207, United States
  • Clinton Township, Michigan 48038, United States
  • Detroit, Michigan 48202, United States
  • Fridley, Minnesota 55432, United States
  • Albuquerque, New Mexico 87106, United States
  • New York, New York, United States
  • Stony Brook, New York 11790, United States
  • Winston-Salem, North Carolina 27104, United States
  • Cleveland, Ohio 44195, United States
  • Portland, Oregon 97210, United States
  • Portland, Oregon 97223, United States
  • Austin, Texas 78759, United States
  • College Station, Texas 77845, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah 84117, United States
  • Lynchburg, Virginia 24501, United States
  • Norfolk, Virginia 23507, United States
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Nov 2015, 12 months.

Results were first posted in Oct 2026, 10 years 11 months after primary completion. A results delay was requested in Jul 2018.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2014
First posted
Oct 27, 2014
StartActual
Nov 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results delay requested
Jul 24, 2018
Results first posted
Oct 1, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 1, 2026 · revised Oct 21, 2026
Enrollment
310→302
Oct 1, 2026
Interventions
Changed SM04554→Topical SM04554 solution; Vehicle→Topical vehicle solution. Added Drug: Topical SM04554 solution. Arm changed Active Arm 1→Topical SM04554 0.15% solution; Active Arm 2→Topical SM04554 0.25% solution; Vehicle Arm→Vehicle
Oct 1, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange From Baseline in nonNon-vellus hair countHair CountTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
  • EditedChange in subject assessmentSubject Assessment of hair growthHair Growth and qualityQualityTime frame: Day 45, Day 90 → Day 45, Day 90, and Day 135
Oct 1, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • EditedChange in hair growthHair Growth as assessedAssessed by the investigatorInvestigatorTime frame: Day 45, Day 90 → Day 45, Day 90, and Day 135
  • EditedImpact of AGA on qualityQuality of lifeLifeTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
  • EditedChange From Baseline in hair densityHair WidthTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
What changed on Oct 21, 2026
  • EditedChange From Baseline in Total Sum of Hair WidthTime frame: Day 45, Day 90, and Day 135
across 2 updates, Oct 1, 2026 – Oct 21, 2026
Show all 2 updates
  1. Oct 21, 2026
    Posted results revised
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline in Total Sum of Hair WidthTime frame: Day 45, Day 90, and Day 135
  2. Oct 1, 2026
    Results posted
    Enrollment 310→302
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange From Baseline in nonNon-vellus hair countHair CountTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
    • EditedChange in subject assessmentSubject Assessment of hair growthHair Growth and qualityQualityTime frame: Day 45, Day 90 → Day 45, Day 90, and Day 135
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedChange in hair growthHair Growth as assessedAssessed by the investigatorInvestigatorTime frame: Day 45, Day 90 → Day 45, Day 90, and Day 135
    • EditedImpact of AGA on qualityQuality of lifeLifeTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
    • EditedChange From Baseline in hair densityHair WidthTime frame: Baseline, Day 45, Day 90 → Day 45, Day 90, and Day 135
    Interventions Changed SM04554→Topical SM04554 solution; Vehicle→Topical vehicle solution. Added Drug: Topical SM04554 solution. Arm changed Active Arm 1→Topical SM04554 0.15% solution; Active Arm 2→Topical SM04554 0.25% solution; Vehicle Arm→Vehicle
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02275351
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Nov 2014
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Oct 1, 2026
Last update
Oct 21, 2026

Study contacts

Yusuf Yazici, M.D.
study director · Biosplice Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalosirvat

Start the discussion